<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284491</url>
  </required_header>
  <id_info>
    <org_study_id>PEAK VP-00070</org_study_id>
    <nct_id>NCT01284491</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0</brief_title>
  <acronym>PRECISE</acronym>
  <official_title>A Prospective, Randomized, Controlled Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Surgical Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Surgical Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate scar quality following incision with the
      PEAK PlasmaBlade 4.0 using the Patient and Observer Scar Assessment Scale (POSAS), and to
      compare these results to equivalently-aged scars formed following incision with a standard
      scalpel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects attended one of two evaluation dates scheduled on January 21, 2011 and February 23,
      2011. During this visit, subjects gave informed consent and were instructed on evaluating
      their breast reduction scars using the Patient Scar Assessment Scale. Following subjects'
      self-evaluation, each subject was evaluated by three evaluators using the Observer Scar
      Assessment Scale.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Termination due to acquisition of PEAK Surgical by Medtronic
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scar Quality</measure>
    <time_frame>0-18 months following breast reduction surgery</time_frame>
    <description>The primary endpoint will be the difference in scar quality (color, thickness, stiffness, pliability, etc.) between the scalpel and PlasmaBlade skin incisions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Macromastia</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PlasmaBlade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PEAK PlasmaBlade 4.0</intervention_name>
    <description>The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.</description>
    <arm_group_label>PlasmaBlade</arm_group_label>
    <other_name>PlasmaBlade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Traditional Electrosurgery with scalpel</intervention_name>
    <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <other_name>Scalpel and electrosurgery</other_name>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 70

          2. Physically healthy, stable weight

          3. Non-smokers, or prior smokers who stopped smoking at least two weeks prior to surgery.

          4. Subject must understand the nature of the procedure and provide written informed
             consent prior to the procedure.

          5. Subject must be willing and able to comply with specified follow-up evaluations.

          6. Subjects who have participated in the PEAK PlasmaBlade bilateral breast reduction
             study.

        Exclusion Criteria:

          1. Age younger than 18 or greater than 70 years old

          2. Anticoagulation therapy which cannot be discontinued

          3. Smoking (continuous; any substance)

          4. Infection (local or systemic)

          5. Cognitive impairment or mental illness

          6. Severe cardiopulmonary deficiencies

          7. Known coagulopathy

          8. Immunocompromised

          9. Prior history of breast cancer

         10. Kidney disease (any type)

         11. Currently taking any medication known to affect healing

         12. Subjects who did not participated in the PEAK PlasmaBlade bilateral breast reduction
             study

         13. Unable to follow instructions or complete follow-up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhay Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gupta Plastic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gupta Plastic Surgery</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <results_first_submitted>November 29, 2012</results_first_submitted>
  <results_first_submitted_qc>November 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 3, 2013</results_first_posted>
  <last_update_submitted>January 3, 2013</last_update_submitted>
  <last_update_submitted_qc>January 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast reduction</keyword>
  <keyword>PlasmaBlade</keyword>
  <keyword>Electrosurgery</keyword>
  <keyword>PEAK Surgical</keyword>
  <keyword>Medtronic Advanced Energy</keyword>
  <keyword>Medtronic</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects' breasts were randomized individually to the PEAK PlasmaBlade or SOC group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Total Study Population</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Study Population</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation. The protocol-specified age range is used for this baseline measure.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Scar Quality</title>
        <description>The primary endpoint will be the difference in scar quality (color, thickness, stiffness, pliability, etc.) between the scalpel and PlasmaBlade skin incisions.</description>
        <time_frame>0-18 months following breast reduction surgery</time_frame>
        <population>An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</population>
        <group_list>
          <group group_id="O1">
            <title>PEAK PlasmaBlade 4.0</title>
            <description>The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.</description>
          </group>
          <group group_id="O2">
            <title>Traditional Electrosurgery With Scalpel</title>
            <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
          </group>
        </group_list>
        <measure>
          <title>Scar Quality</title>
          <description>The primary endpoint will be the difference in scar quality (color, thickness, stiffness, pliability, etc.) between the scalpel and PlasmaBlade skin incisions.</description>
          <population>An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PEAK PlasmaBlade 4.0</title>
          <description>The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.</description>
        </group>
        <group group_id="E2">
          <title>Traditional Electrosurgery With Scalpel</title>
          <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Swain, PhD</name_or_title>
      <organization>Medtronic Surgical Technologies</organization>
      <phone>(+1-603) 294-5428</phone>
      <email>robert.e.swain@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

